We are live on ! Find out more
FTM

First Turn Management Portfolio holdings

AUM $895M
1-Year Est. Return 261.28%
This Fund
S&P 500
This Quarter Est. Return
-0.83%
1 Year Est. Return
+261.28%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$558M
AUM Growth
-$73.3M
Cap. Flow
-$37.5M
Cap. Flow %
-6.71%
Top 10 Hldgs %
44.81%
Holding
45
New
7
Increased
11
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$20.4M
2
JANX icon
Janux Therapeutics
JANX
+$20.3M
3
EXAS
Exact Sciences
EXAS
+$19.3M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$14.9M
5
APGE icon
Apogee Therapeutics
APGE
+$12.9M

Top Sells

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$17.9M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$16.4M
3
ESTA icon
Establishment Labs
ESTA
+$15.4M
4
RGEN icon
Repligen
RGEN
+$13.2M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
26
Oric Pharmaceuticals
ORIC
$1.25B
$11.7M 2.1%
1,451,037
– –
ACLX
27
DELISTED
Arcellx
ACLX
$11.7M 2.09%
152,356
-61,942
-29% -$5.35M
APGE icon
28
Apogee Therapeutics
APGE
$10.2B
$11.4M 2.05%
+252,725
New +$12.9M
HROW icon
29
Harrow
HROW
$1.43B
$10.2M 1.83%
304,874
-21,708
-7% -$961K
BHVN icon
30
Biohaven
BHVN
$2.16B
$9.8M 1.76%
262,442
-53,374
-17% -$2.49M
CRMD icon
31
CorMedix
CRMD
$617M
$8.27M 1.48%
+1,021,421
New +$10.2M
SPRY icon
32
ARS Pharmaceuticals
SPRY
$590M
$6.26M 1.12%
593,291
– –
BCAX
33
Bicara Therapeutics
BCAX
$1.78B
$6.03M 1.08%
346,170
-216,221
-38% -$4.5M
BPMC
34
DELISTED
Blueprint Medicines
BPMC
$5.86M 1.05%
67,143
-111,786
-62% -$10.2M
SNDX icon
35
Syndax Pharmaceuticals
SNDX
$1.84B
$5.84M 1.05%
441,587
-745,578
-63% -$12.8M
PRAX icon
36
Praxis Precision Medicines
PRAX
$9.07B
$3.5M 0.63%
+45,536
New +$3.29M
CYTK icon
37
Cytokinetics
CYTK
$11B
– –
-223,147
Closed -$11.8M
ESTA icon
38
Establishment Labs
ESTA
$2.72B
– –
-357,003
Closed -$15.4M
KALV
39
DELISTED
KalVista Pharmaceuticals
KALV
– –
-355,000
Closed -$4.11M
KRYS icon
40
Krystal Biotech
KRYS
$9.88B
– –
-67,942
Closed -$12.4M
RCKT icon
41
Rocket Pharmaceuticals
RCKT
$348M
– –
-621,306
Closed -$11.5M
RGEN icon
42
Repligen
RGEN
$7.44B
– –
-88,714
Closed -$13.2M
RLAY icon
43
Relay Therapeutics
RLAY
$4.02B
– –
-1,226,354
Closed -$8.68M
TMDX icon
44
Transmedics
TMDX
$2.5B
– –
-114,247
Closed -$17.9M
VRTX icon
45
Vertex Pharmaceuticals
VRTX
$121B
– –
-35,222
Closed -$16.4M
1
2

Similar funds

WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
IWP
IAG Wealth Partners Waukesha, Wisconsin $896M AUM 15.29% 1-Year Est. Return
SI
Squadra Investments Rio De Janeiro, Brazil $894M AUM 33.04% 1-Year Est. Return
GEM
Global Endowment Management Charlotte, North Carolina $896M AUM 13.86% 1-Year Est. Return
BFFIM
Baring Fintech Fund III Managers St Peter Port, Guernsey $893M AUM 20.23% 1-Year Est. Return
WP
WealthShield Partners Cary, North Carolina $898M AUM 19.35% 1-Year Est. Return
SFM
Signet Financial Management Parsippany, New Jersey $892M AUM 23.24% 1-Year Est. Return
PCM
Prime Capital Management Hong Kong $891M AUM 83.14% 1-Year Est. Return

First Turn Management's Q4 2024 Portfolio in Review

As of Q4 2024, First Turn Management held 45 positions worth $558M, down 12% from $632M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

First Turn Management withdrew a net $37.5M in Q4 2024, closing 9 positions and reducing 13 holdings. Its most notable exit was Transmedics, an estimated $17.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, First Turn Management opened a new position in Revolution Medicines worth $17.7M.

  • First Turn Management's largest Q4 2024 buy was Revolution Medicines: 403,915 shares worth $17.7M.
  • First Turn Management added most to Xenon Pharmaceuticals in Q4 2024, an estimated $14.9M increase.
  • First Turn Management's biggest Q4 2024 reduction was Syndax Pharmaceuticals, cutting an estimated $12.8M.
  • First Turn Management fully exited Transmedics in Q4 2024, selling an estimated $17.9M.
  • First Turn Management's ten largest holdings make up 45% of its $558M portfolio in Q4 2024.
  • First Turn Management opened 7 new positions and closed 9 in Q4 2024.
  • First Turn Management's portfolio value fell 12% quarter-over-quarter to $558M.

Based on First Turn Management's 13F filing for Q4 2024, filed 14 Feb 2025.